Brief: Clarity Pharmaceuticals Says Phase Iii Clarify Trial In Prostate Cancer Commences
30/11/2023 01:07
Nov 30 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* PHASE III CLARIFY TRIAL IN PROSTATE CANCER COMMENCES
Source text for Eikon: ID:nASXbwk9yd
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial